Sunflower Therapeutics

Sunflower Therapeutics was awarded a Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), providing $2 million to support a company project.

Sunflower Therapeutics PBC aims to help more medicines and protein-based products reach patients and consumers worldwide. Its protein manufacturing solutions include microbial hosts, bioprocesses, biomanufacturing equipment, and instrument controls.

Sunflower is a women-owned and led biotechnology company with a team of scientists and engineers. Its expertise includes fermentation and purification process development, biopharmaceutical manufacturing, and quality management.

Sunflower Therapeutics was founded in 2018 to increase the availability of biologic medicines through the development of manufacturing technologies.

The company works with global biopharmaceutical companies, vaccine manufacturers, biotech start-ups, academic researchers, and global think tanks to help products become reality.

Sunflower Therapeutics is a biotechnology company delivering next-generation protein manufacturing solutions designed for anyone to use anywhere.

Sunflower Therapeutics’ Privacy Policy explains its practices for collecting, using, and disclosing information provided through its website and social media pages.

The terms govern access to and use of www.sunflowertx.com and other websites that link to them, along with associated services, materials, and tools.